RecruitingNCT07193888

Navitor Japan Study

Navitor Japan Post-Market Study

Sponsor

Abbott Medical Devices

Enrollment

100 participants

Start Date

Oct 30, 2025

Study Type

OBSERVATIONAL

Conditions

Severe aortic stenosis

Summary

The Navitor Japan Study is designed to evaluate the safety and performance of the Navitor™ valve used in combination with the FlexNav™ delivery system in a contemporary, real-world setting.

Eligibility

Min Age: 18 YearsMax Age: 100 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called Navitor Transcatheter Aortic Valve Implantation for people with severe aortic stenosis. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 18 Years to 100 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICENavitor Transcatheter Aortic Valve Implantation

Subjects will undergo transcatheter aortic valve implantation (TAVI) with the Navitor valve, the FlexNav Delivery system and the Navitor Loading System.

Locations(3)

Kokura Memorial Hospital

Fukuoka, Japan

Shonan Kamakura General Hospital

Kanagawa, Japan

Osaka Keisatsu Hospital

Osaka, Japan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07193888

Related Trials

A Clinical Trial Assessing the Safety and Effectiveness of the DurAVR® THV System

NCT071942651 location

Aspirin vs Clopidogrel After TAVR

NCT054936571 location

A Registry to Assess the Efficacy and Safety of Transcatheter Treatment for Aortic Valve Disease at the IRCCS Policlinico San Matteo Foundation in Pavia (Italy).

NCT075963941 location

CLEAR-AS: CT-FFR-Guided Revascularization in Patients With Severe Aortic Stenosis

NCT074693711 location

Safety and Efficacy of the RENATUS® Transcatheter Aortic Valve System for the Treatment of Severe Aortic Stenosis

NCT074143424 locations